Drug cocktail boosts ovarian cancer survival time

June 2, 2012

A drug cocktail that combines chemotherapy with Avastin was shown to double the amount of time patients lived without progression of ovarian cancer, according to research released Saturday.

Also known as bevacizumab and marketed as Avastin by the Swiss Roche, the drug could help women who have a resistant form of the cancer, researchers said.

"For the first time in platinum resistant ovarian cancer, we have been able to significantly improve progression free survival with a combination therapy," said lead study author Eric Pujade-Lauraine, a professor at Universite de Paris Descartes.

"These results are very significant because the addition of bevacizumab offers a new treatment option for the 20 percent of women who have primary platinum resistant disease, as well as those whose disease later becomes platinum-resistant."

The international, randomized phase III clinical trial included 361 patients with ovarian cancer. Some received bevacizumab in addition to standard chemotherapies; others received chemo treatments alone.

The median time of progression free survival was 6.7 months in the combination therapy group, compared to 3.4 months in chemotherapy alone group.

Previous research has shown that can be effective as a first and second line treatment against ovarian cancer, and future studies may shed more light on when how long to administer it.

The latest research was presented at the annual conference of the in Chicago.

Some 230,000 women are diagnosed each year worldwide with . About 70 percent of patients die within five years of diagnosis.

Explore further: New drug combination slows tumor growth for recurrent ovarian cancer

Related Stories

New drug combination slows tumor growth for recurrent ovarian cancer

June 6, 2011
Bevacizumab (Avastin) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer, according to a new study. Results from the phase III "OCEANS" trial were presented today by ...

Targeted therapy extends progression-free survival of patients with advanced ovarian cancer

December 28, 2011
Targeted drugs, which block or disrupt particular molecules involved in the growth of tumors, have been shown to be effective treatments against many types of cancer. A new phase 3 clinical trial conducted by the Gynecologic ...

Experimental drug inhibits cell signaling pathway and slows ovarian cancer growth

April 15, 2011
An experimental drug that blocks two points of a crucial cancer cell signaling pathway inhibits the growth of ovarian cancer cells and significantly increases survival in an ovarian cancer mouse model, a study at UCLA's Jonsson ...

Recommended for you

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.